Stay updated on Aurinia Pharmaceuticals Press Releases

Sign up to get notified when there's something new on the Aurinia Pharmaceuticals Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Aurinia Pharmaceuticals Press Releases page

  1. Check
    yesterday
    Change Detected
    Summary
    A new news item announcing Aurinia's financial results for the three and six months ended June 30, 2026, with the timestamp August 6, 2026 8:00 AM EDT, was added to the News page, and the previously listed notice of participation in the Jefferies London Healthcare Conference from November 14, 2024 was removed.
    Difference
    1%
    Check dated 2026-08-08T18:14:29.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    No Change Detected
  5. Check
    29 days ago
    Change Detected
    Summary
    A new news item announces the PRESERVE study initiation with timing details, expanding coverage of Aurinia's clinical program; an older news item about Craig Johnson's board appointment has been removed.
    Difference
    1%
    Check dated 2026-07-11T00:00:30.000Z thumbnail image
  6. Check
    65 days ago
    Change Detected
    Summary
    A new LUPKYNIS press release headline with a June 4, 2026 7:00 AM EDT timestamp was added to the News page, highlighting a significant clinical result. The listing also removes an older Growth and AUR200 Development entry and related metadata from the page.
    Difference
    1%
    Check dated 2026-06-05T09:51:29.000Z thumbnail image
  7. Check
    94 days ago
    Change Detected
    Summary
    Adds Aurinia's press release for the three months ended March 31, 2026 with the May 7, 2026 timestamp. Removes an older notice about releasing third-quarter 2024 results.
    Difference
    1%
    Check dated 2026-05-07T23:12:56.000Z thumbnail image
  8. Check
    129 days ago
    Change Detected
    Summary
    Adds a press release announcing Aurinia's acquisition of Kezar Life Sciences for $6.955 per share in cash plus a contingent value right. Also removes two older press releases related to Lupus Nephritis data and LUPKYNIS findings from 2024.
    Difference
    1%
    Check dated 2026-04-02T00:20:14.000Z thumbnail image
  9. Check
    137 days ago
    Change Detected
    Summary
    Added the 'Aurinia Announces Management Transition' press release dated March 23, 2026. Removed older entries including the 2024 'Aurinia Announces Japan Approval of LUPKYNIS' release and the 'Voclosporin to Treat Lupus Nephritis' item from the press releases list.
    Difference
    1%
    Check dated 2026-03-25T20:46:46.000Z thumbnail image

Stay in the know with updates to Aurinia Pharmaceuticals Press Releases

Enter your email address, and we'll notify you when there's something new on the Aurinia Pharmaceuticals Press Releases page.